Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension

@article{Barroso1999DominantNM,
  title={Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension},
  author={I. Barroso and M. Gurnell and V. E. Crowley and M. Agostini and J. Schwabe and M. Soos and G. Maslen and T. Williams and H. Lewis and A. Schafer and V. Chatterjee and S. O'rahilly},
  journal={Nature},
  year={1999},
  volume={402},
  pages={880-883}
}
  • I. Barroso, M. Gurnell, +9 authors S. O'rahilly
  • Published 1999
  • Medicine, Biology
  • Nature
  • Thiazolidinediones are a new class of antidiabetic agent that improve insulin sensitivity and reduce plasma glucose and blood pressure in subjects with type 2 diabetes. Although these agents can bind and activate an orphan nuclear receptor, peroxisome proliferator-activated receptor gamma (PPARγ), there is no direct evidence to conclusively implicate this receptor in the regulation of mammalian glucose homeostasis. Here we report two different heterozygous mutations in the ligand-binding domain… CONTINUE READING
    The hormone resistin links obesity to diabetes
    • 4,242
    The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes
    • 1,740
    • PDF
    Fat and beyond: the diverse biology of PPARgamma.
    • 1,571
    Roles of PPARs in health and disease
    • 1,756
    • PDF
    The Many Faces of PPARγ
    • 1,019
    The mechanisms of action of PPARs.
    • 2,101
    • PDF

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 38 REFERENCES
    Loss-of-Function Mutations in PPARγ Associated with Human Colon Cancer
    • 464